pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·1h ago·1 min read
save

SonoThera appoints former BridgeBio chief medical officer Adam Shaywitz

Oct 2, 2026·read at STAT ↗Neutral

STAT+ columnist Ed Silverman notes that the pharmaceutical industry continues to see staff changes, with a regular feature highlighting individual moves.

SonoThera announced the hiring of Adam Shaywitz as its new chief medical officer. The appointment was highlighted in the latest “up and down the ladder” column.

Shaywitz comes to SonoThera from BridgeBio, where he previously held the same chief medical officer position. The move reflects ongoing talent shifts among biotech firms.

The column invites readers to share similar personnel updates for future coverage.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Up and down the ladder: The latest comings and goings”

read at STAT ↗
466 words · retrieved 48m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Beam Therapeutics Inc.LILLYNOVOOVERSEASRISING
drugs
Obesity3
topics
Obesity3

related stories

  • 2h agoSTAT+: Pharmalittle: We’re reading about the 340B drug pilot program, an obesity drug disappointment, and moreSTAT
  • 1d agoSTAT+: Pharmalittle: We’re reading about a plan to lower Medicare drug prices, a Lilly obesity drug, and moreSTAT
  • Sep 22Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030BioSpace
  • 22h agoMistrust in science and a juicy gene-editing lawsuitSTAT
  • 2d agoSTAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trialSTAT